The DOI matches its Crossref record; 108 of the 108 references it cites were found in a registry or an index.
EGFR Signaling and Drug Discovery
Abstract
Dysregulation of human epidermal growth factor receptor (ErbB/HER) pathways by over-expression or constitutive activation can promote tumor processes including angiogenesis and metastasis and is associated with poor prognosis in many human malignancies. In addition to cancer, ErbB signaling has also been implicated in cardiovascular and neurodegenerative diseases. Conversely, inhibition of ErbB pathways with targeted agents, such as monoclonal antibodies (MoAbs) or tyrosine kinase inhibitors (TKIs), blocks cell cycle progression, inhibits the production of pro-angiogenic factors and induces apoptosis in numerous in vitro and xenograft models. Accordingly, the ErbB receptor family with their most prominent members EGFR and HER-2 represents validated targets for anti-cancer therapy, and anti-ErbB MoAbs (cetuximab, panitumumab, and trastuzumab) and TKIs (gefitinib, erlotinib, and lapatinib) have now been approved for the treatment of advanced colorectal cancer, squamous cell carcinoma of the head and neck, advanced non-small-cell lung cancer, as well as pancreatic and breast cancer. Although results have been encouraging, more work remains to be done.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Slamon, D. J., Clark, G. M., Wong, S. G., Levin, W. J., Ullrich, A., & McGuire, W. L. (1987) · Science · doi:10.1126/science.3798106 · Cited by 11,760 · cited 1×
“In addition to EGFR (ERBB1), HER-2 (ERBB2) was first recognized over 20 years ago when it was found to be overexpressed in 30p of invasive breast cancers and shown to correlate inversely with time to tumor recurrence and overall survival (OS) [”
BackgroundLynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian Cancer
Slamon, D. J., Godolphin, W., Jones, L. A., Holt, J. A., Wong, S. G., Keith, D. E., Levin, W. J., Stuart, S. G., Udove, J., Ullrich, A., et al. (1989) · Science · doi:10.1126/science.2470152 · Cited by 6,816
The phosphatidylinositol 3-Kinase–AKT pathway in human cancer
Vivanco, I., & Sawyers, C. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc839 · Cited by 6,056
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419 · cited 1×
“The recently reported phase III BR.21 clinical trial demonstrated that erlotinib, unlike gefitinib, produced a survival advantage relative to placebo in patients with incurable NSCLC who had not responded to one or two prior chemotherapy regimens. In this study, over 700 patients were randomly assigned in a 2:1 ratio…”
BackgroundInfluentialRadiotherapy plus Cetuximab for Squamous-Cell Carcinoma of the Head and Neck
Bonner, J. A., Harari, P. M., Giralt, J., Azarnia, N., Shin, D. M., Cohen, R. B., Jones, C. U., Sur, R., Raben, D., Jassem, J., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053422 · Cited by 5,115
Cunningham, D., Humblet, Y., Siena, S., Khayat, D., Bleiberg, H., Santoro, A., Bets, D., Mueser, M., Harstrick, A., Verslype, C., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa033025 · Cited by 5,035 · cited 1×
“Regulatory approval of cetuximab was based on a pivotal European trial (BOND), where patients were randomly assigned to receive cetuximab alone or cetuximab in combination with CPT-11. The study of >300 patients showed a response rate of 22.9 and 10.8p (p = 0.007) for the combination and mono-chemotherapy groups, resp…”
InfluentialDarnell, J. E. (1997) · Science · doi:10.1126/science.277.5332.1630 · Cited by 3,979
Cetuximab and Chemotherapy as Initial Treatment for Metastatic Colorectal Cancer
Van Cutsem, E., Köhne, C.-H., Hitre, E., Zaluski, J., Chang Chien, C.-R., Makhson, A., D'Haens, G., Pintér, T., Lim, R., Bodoky, G., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0805019 · Cited by 3,877
Moore, M. J., Goldstein, D., Hamm, J., Figer, A., Hecht, J. R., Gallinger, S., Au, H. J., Murawa, P., Walde, D., Wolff, R. A., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9525 · Cited by 3,848
K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer
Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., O'Callaghan, C. J., Tu, D., Tebbutt, N. C., Simes, R. J., Chalchal, H., Shapiro, J. D., Robitaille, S., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0804385 · Cited by 3,622
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019 · cited 1×
“Other promising therapeutic targets include mTOR, PI3K, SRC, MET and MEK (table 3 ). Interestingly, a recent study by Motzer et al. [”
BackgroundFukuoka, M., Yano, S., Giaccone, G., Tamura, T., Nakagawa, K., Douillard, J.-Y., Nishiwaki, Y., Vansteenkiste, J., Kudoh, S., Rischin, D., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.038 · Cited by 2,874
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets
Clynes, R. A., Towers, T. L., Presta, L. G., & Ravetch, J. V. (2000) · Nature Medicine · doi:10.1038/74704 · Cited by 2,768 · cited 1×
“However, some recent in vitro and in vivo data suggest that the efficacy of trastuzumab depends on the interaction between HER-2-mediated signal transduction and interference with antibody-dependent cell cytotoxicity [”
BackgroundEpidermal growth factor-related peptides and their receptors in human malignancies
Salomon, D. S., Brandt, R., Ciardiello, F., & Normanno, N. (1995) · Critical Reviews in Oncology/Hematology · doi:10.1016/1040-8428(94)00144-i · Cited by 2,690
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Close similarity of epidermal growth factor receptor and v-erb-B oncogene protein sequences
Downward, J., Yarden, Y., Mayes, E., Scrace, G., Totty, N., Stockwell, P., Ullrich, A., Schlessinger, J., & Waterfield, M. D. (1984) · Nature · doi:10.1038/307521a0 · Cited by 2,516
The STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278
Zhong, Z., Wen, Z., & Darnell, J. E. (1994) · Science · doi:10.1126/science.8140422 · Cited by 2,070 · cited 1×
“STAT proteins interact with phosphotyrosine residues via their SH2 domain and, upon dimerization, translocate to the nucleus and induce the expression of specific target genes [”
BackgroundEGF–ERBB signalling: towards the systems level
Citri, A., & Yarden, Y. (2006) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1962 · Cited by 2,004
Van Cutsem, E., Peeters, M., Siena, S., Humblet, Y., Hendlisz, A., Neyns, B., Canon, J.-L., Van Laethem, J.-L., Maurel, J., Richardson, G., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.1620 · Cited by 1,979 · cited 1×
“In a recent phase III study conducted by Van Cutsem et al. [”
BackgroundSystematic Review of Microsatellite Instability and Colorectal Cancer Prognosis
Popat, S., Hubner, R., & Houlston, R. S. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.086 · Cited by 1,830
Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias
Talpaz, M., Shah, N. P., Kantarjian, H., Donato, N., Nicoll, J., Paquette, R., Cortes, J., O'Brien, S., Nicaise, C., Bleickardt, E., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa055229 · Cited by 1,760
Bowman, T., Garcia, R., Turkson, J., & Jove, R. (2000) · Oncogene · doi:10.1038/sj.onc.1203527 · Cited by 1,743
Giaccone, G., Herbst, R. S., Manegold, C., Scagliotti, G., Rosell, R., Miller, V., Natale, R. B., Schiller, J. H., von Pawel, J., Pluzanska, A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.001 · Cited by 1,716
Herbst, R. S., Giaccone, G., Schiller, J. H., Natale, R. B., Miller, V., Manegold, C., Scagliotti, G., Rosell, R., Oliff, I., Reeves, J. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.215 · Cited by 1,707
Saltz, L. B., Meropol, N. J., Loehrer, P. J., Needle, M. N., Kopit, J., & Mayer, R. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.10.182 · Cited by 1,694
The SH2 and SH3 domain-containing protein GRB2 links receptor tyrosine kinases to ras signaling
Lowenstein, E. J., Daly, R. J., Batzer, A. G., Li, W., Margolis, B., Lammers, R., Ullrich, A., Skolnik, E. Y., Bar-Sagi, D., & Schlessinger, J. (1992) · Cell · doi:10.1016/0092-8674(92)90167-b · Cited by 1,631
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
Di Nicolantonio, F., Martini, M., Molinari, F., Sartore-Bianchi, A., Arena, S., Saletti, P., De Dosso, S., Mazzucchelli, L., Frattini, M., Siena, S., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.18.0786 · Cited by 1,591 · cited 1×
“KRAS and PI3K mutations in turn dysregulate mechanisms modulating tumor angiogenesis and apoptosis that are normally controlled by multiple homeostatic mechanisms, including signals from the EGFR. Other promising markers of resistance to EGFR-targeted therapies include BRAF mutations and PTEN expression. In a recent s…”
BackgroundLièvre, A., Bachet, J.-B., Boige, V., Cayre, A., Le Corre, D., Buc, E., Ychou, M., Bouché, O., Landi, B., Louvet, C., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.5906 · Cited by 1,444
Chemotherapy, Bevacizumab, and Cetuximab in Metastatic Colorectal Cancer
Tol, J., Koopman, M., Cats, A., Rodenburg, C. J., Creemers, G. J. M., Schrama, J. G., Erdkamp, F. L. G., Vos, A. H., van Groeningen, C. J., Sinnige, H. A. M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0808268 · Cited by 1,341
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227
Dual Role of Phosphatidylinositol-3,4,5-trisphosphate in the Activation of Protein Kinase B
Stokoe, D., Stephens, L. R., Copeland, T., Gaffney, P. R. J., Reese, C. B., Painter, G. F., Holmes, A. B., McCormick, F., & Hawkins, P. T. (1997) · Science · doi:10.1126/science.277.5325.567 · Cited by 1,201
Khambata-Ford, S., Garrett, C. R., Meropol, N. J., Basik, M., Harbison, C. T., Wu, S., Wong, T. W., Huang, X., Takimoto, C. H., Godwin, A. K., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.5437 · Cited by 1,125
A Unique Structure for Epidermal Growth Factor Receptor Bound to GW572016 (Lapatinib)
Wood, E. R., Truesdale, A. T., McDonald, O. B., Yuan, D., Hassell, A., Dickerson, S. H., Ellis, B., Pennisi, C., Horne, E., Lackey, K., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1168 · Cited by 1,122
Yeatman, T. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1366 · Cited by 1,113
Transcriptional Regulation by Extracellular signals: Mechanisms and Specificity
Hill, C. S., & Treisman, R. (1995) · Cell · doi:10.1016/0092-8674(95)90403-4 · Cited by 1,012
Konecny, G. E., Pegram, M. D., Venkatesan, N., Finn, R., Yang, G., Rahmeh, M., Untch, M., Rusnak, D. W., Spehar, G., Mullin, R. J., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-1182 · Cited by 914
The Epidermal Growth Factor Receptor Pathway: A Model for Targeted Therapy
Scaltriti, M., & Baselga, J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1554 · Cited by 913
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
ErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Insulin-Like Growth Factor-I Receptor Signaling and Resistance to Trastuzumab (Herceptin)
Lu, Y., Zi, X., Zhao, Y., Mascarenhas, D., & Pollak, M. (2001) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/93.24.1852 · Cited by 882
De Roock, W., Piessevaux, H., De Schutter, J., Janssens, M., De Hertogh, G., Personeni, N., Biesmans, B., Van Laethem, J.-L., Peeters, M., Humblet, Y., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdm496 · Cited by 827
Kawamoto, T., Sato, J. D., Le, A., Polikoff, J., Sato, G. H., & Mendelsohn, J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.5.1337 · Cited by 791
Bromberg, J. (2002) · Journal of Clinical Investigation · doi:10.1172/jci15617 · Cited by 770
Sartore-Bianchi, A., Martini, M., Molinari, F., Veronese, S., Nichelatti, M., Artale, S., Di Nicolantonio, F., Saletti, P., De Dosso, S., Mazzucchelli, L., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2466 · Cited by 739
Di Fiore, F., Blanchard, F., Charbonnier, F., Le Pessot, F., Lamy, A., Galais, M. P., Bastit, L., Killian, A., Sesboüé, R., Tuech, J. J., et al. (2007) · British Journal of Cancer · doi:10.1038/sj.bjc.6603685 · Cited by 734
Epidermal Growth Factor Receptor Targeting in Cancer
MENDELSOHN, J., & BASELGA, J. (2006) · Seminars in Oncology · doi:10.1053/j.seminoncol.2006.04.003 · Cited by 693
Chakravarti, A., Loeffler, J. S., & Dyson, N. J. (2002) · PubMed · Cited by 542
Biochemical and Clinical Implications of the ErbB/HER Signaling Network of Growth Factor Receptors
(1999) · Advances in Cancer Research · doi:10.1016/s0065-230x(08)60784-8 · Cited by 540
Lenz, H.-J., Van Cutsem, E., Khambata-Ford, S., Mayer, R. J., Gold, P., Stella, P., Mirtsching, B., Cohn, A. L., Pippas, A. W., Azarnia, N., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.7595 · Cited by 528
Self-citationYu, J., Zhang, Y., McIlroy, J., Rordorf-Nikolic, T., Orr, G. A., & Backer, J. M. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.3.1379 · Cited by 520
Why the Epidermal Growth Factor Receptor? The Rationale for Cancer Therapy
Baselga, J. (2002) · The Oncologist · doi:10.1634/theoncologist.7-2004-2 · Cited by 510
Zhang, W., Gordon, M., Schultheis, A. M., Yang, D. Y., Nagashima, F., Azuma, M., Chang, H.-M., Borucka, E., Lurje, G., Sherrod, A. E., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.8021 · Cited by 482
Self-citationHierarchy of binding sites for Grb2 and Shc on the epidermal growth factor receptor.
Batzer, A. G., Rotin, D., Ureña, J. M., Skolnik, E. Y., & Schlessinger, J. (1994) · Molecular and Cellular Biology · doi:10.1128/mcb.14.8.5192 · Cited by 479
Development of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapy
Yang, X. (2001) · Critical Reviews in Oncology/Hematology · doi:10.1016/s1040-8428(00)00134-7 · Cited by 463
Biological effects in vitro of monoclonal antibodies to human epidermal growth factor receptors.
Sato, J. D., Kawamoto, T., Le, A. D., Mendelsohn, J. M., Polikoff, J., & SATO, G. H. (1983) · PubMed · Cited by 458
Fan, Z., Baselga, J. M., Masui, H., & Mendelsohn, J. M. (1993) · PubMed · Cited by 456
Gill, G. N., Kawamoto, T., Cochet, C., Le, A., Sato, J. D., Masui, H., McLeod, C., & Mendelsohn, J. (1984) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)42857-2 · Cited by 455
Masui, H., Kawamoto, T., Sato, J. D., Wolf, B., Sato, G., & Mendelsohn, J. (1984) · Journal of Urology · doi:10.1016/s0022-5347(17)50005-1 · Cited by 446
Haura, E. B., Turkson, J., & Jove, R. (2005) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0195 · Cited by 430
Mismatch repair proficiency and in vitro response to 5-fluorouracil
Carethers, J. M., Chauhan, D. P., Fink, D., Nebel, S., Bresalier, R. S., Howell, S. B., & Boland, C. R. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70558-5 · Cited by 429
Arteaga, C. L. (2001) · PubMed · Cited by 397
Carpenter, C. L., Auger, K. R., Chanudhuri, M., Yoakim, M., Schaffhausen, B., Shoelson, S., & Cantley, L. C. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(18)98375-4 · Cited by 388
Wu, X., Fan, Z., Masui, H., Rosen, N., & Mendelsohn, J. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117871 · Cited by 381
Dawson, J. P., Berger, M. B., Lin, C.-C., Schlessinger, J., Lemmon, M. A., & Ferguson, K. M. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.17.7734-7742.2005 · Cited by 297
Prenen, H., De Schutter, J., Jacobs, B., De Roock, W., Biesmans, B., Claes, B., Lambrechts, D., Van Cutsem, E., & Tejpar, S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2961 · Cited by 291
Regulation of MAP kinase activity by peptide receptor signalling pathway: Paradigms of multiplicity
Liebmann, C. (2001) · Cellular Signalling · doi:10.1016/s0898-6568(01)00192-9 · Cited by 287
Martin, G. S. (2003) · Cancer Cell · doi:10.1016/s1535-6108(03)00216-2 · Cited by 281
Sridhar, S. S., Seymour, L., & Shepherd, F. A. (2003) · The Lancet Oncology · doi:10.1016/s1470-2045(03)01137-9 · Cited by 279
Epidermal growth factor receptor biology (IMC-C225)
Kim, E. S., Khuri, F. R., & Herbst, R. S. (2001) · Current Opinion in Oncology · doi:10.1097/00001622-200111000-00014 · Cited by 242
Bokemeyer, C., Bondarenko, I., Hartmann, J. T., De Braud, F. G., Volovat, C., Nippgen, J., Stroh, C., Celik, I., & Koralewski, P. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2008.26.15_suppl.4000 · Cited by 240
Molecular determinants of cetuximab efficacy.
Vallböhmer, D., Zhang, W., Gordon, M., Yang, D. Y., Yun, J., Press, O. A., Rhodes, K. E., Sherrod, A. E., Iqbal, S., Danenberg, K. D., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.100 · Cited by 234
Self-citationTreatment for Advanced Tumors: Src Reclaims Center Stage
Summy, J. M., & Gallick, G. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2692 · Cited by 225
Interaction of Ras and Raf in intact mammalian cells upon extracellular stimulation.
Hallberg, B., Rayter, S. I., & Downward, J. (1994) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)41718-2 · Cited by 218
Foon, K. A., Yang, X.-D., Weiner, L. M., Belldegrun, A. S., Figlin, R. A., Crawford, J., Rowinsky, E. K., Dutcher, J. P., Vogelzang, N. J., Gollub, J., et al. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2003.09.098 · Cited by 218
Association with Membrane Protrusions Makes ErbB2 an Internalization-resistant Receptor
Hommelgaard, A. M., Lerdrup, M., & van Deurs, B. (2004) · Molecular Biology of the Cell · doi:10.1091/mbc.e03-08-0596 · Cited by 210
Molecular Mechanisms of Resistance to Therapies Targeting the Epidermal Growth Factor Receptor
Camp, E. R., Summy, J., Bauer, T. W., Liu, W., Gallick, G. E., & Ellis, L. M. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.397.11.1 · Cited by 210
Regulation of the p85/p110α Phosphatidylinositol 3′-Kinase
Yu, J., Wjasow, C., & Backer, J. M. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.46.30199 · Cited by 181
Personeni, N., Fieuws, S., Piessevaux, H., De Hertogh, G., De Schutter, J., Biesmans, B., De Roock, W., Capoen, A., Debiec-Rychter, M., Van Laethem, J.-L., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0449 · Cited by 174
Andl, C. D., Mizushima, T., Oyama, K., Bowser, M., Nakagawa, H., & Rustgi, A. K. (2004) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00253.2004 · Cited by 174
Survival of colorectal cancer patients in Europe during the period 1978–1989
Gatta, G., Faivre, J., Capocaccia, R., & de Leòn, M. P. (1998) · European Journal of Cancer · doi:10.1016/s0959-8049(98)00327-x · Cited by 169
Rusnak, D. W., Alligood, K. J., Mullin, R. J., Spehar, G. M., Arenas‐Elliott, C., Martin, A. ‐., Degenhardt, Y., Rudolph, S. K., Jr Haws, T. F., Hudson‐Curtis, B. L., et al. (2007) · Cell Proliferation · doi:10.1111/j.1365-2184.2007.00455.x · Cited by 168
STAT5b, a Mediator of Synergism between c-Src and the Epidermal Growth Factor Receptor
Kloth, M. T., Laughlin, K. K., Biscardi, J. S., Boerner, J. L., Parsons, S. J., & Silva, C. M. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m207289200 · Cited by 166
EGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment
Press, M. F., & Lenz, H.-J. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 163
Self-citationRational bases for the development of EGFR inhibitors for cancer treatment
Bianco, R., Gelardi, T., Damiano, V., Ciardiello, F., & Tortora, G. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.05.008 · Cited by 158
Bleeker, W. K., van Bueren, J. J. L., van Ojik, H. H., Gerritsen, A. F., Pluyter, M., Houtkamp, M., Halk, E., Goldstein, J., Schuurman, J., van Dijk, M. A., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.7.4699 · Cited by 152
Lapatinib in the treatment of breast cancer
Higa, G. M., & Abraham, J. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.9.1183 · Cited by 151
Iwakura, Y., Piao, Y., Mizuno, M., Takei, N., Kakita, A., Takahashi, H., & Nawa, H. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03073.x · Cited by 147
Rohrbach, S., Yan, X., Weinberg, E. O., Hasan, F., Bartúnek, J., Marchionni, M. A., & Lorell, B. H. (1999) · Circulation · doi:10.1161/01.cir.100.4.407 · Cited by 145
Cascinu, S., Berardi, R., Labianca, R., Siena, S., Falcone, A., Aitini, E., Barni, S., Costanzo, F. D., Dapretto, E., Tonini, G., et al. (2008) · The Lancet Oncology · doi:10.1016/s1470-2045(07)70383-2 · Cited by 136
Hemming, A. W., Davis, N. L., Kluftinger, A., Robinson, B., Quenville, N. F., Liseman, B., & Lcriche, J. (1992) · Journal of Surgical Oncology · doi:10.1002/jso.2930510304 · Cited by 128
Steiner, P., Joynes, C. J., Bassi, R., Wang, S., Tonra, J. R., Hadari, Y. R., & Hicklin, D. J. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1887 · Cited by 127
A structure-based model for ligand binding and dimerization of EGF receptors
Klein, P., Mattoon, D., Lemmon, M. A., & Schlessinger, J. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307285101 · Cited by 125
Zhang, W., Gordon, M. A., Press, O. A., Rhodes, K. E., Vallböhmer, D., Yang, D., Park, D. S., Fazzone, W., Schultheis, A. M., Sherrod, A. E., et al. (2006) · Pharmacogenetics and Genomics · doi:10.1097/01.fpc.0000220562.67595.a5 · Cited by 122
Self-citationLurje, G., Nagashima, F., Zhang, W., Yang, D., Chang, H. M., Gordon, M. A., El-Khoueiry, A. B., Husain, H., Wilson, P. M., Ladner, R. D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-5165 · Cited by 121
Self-citationPérez-Torres, M., Guix, M., González, A., & Arteaga, C. L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m607958200 · Cited by 99
Nuclear Signaling by Receptor Tyrosine Kinases: The First Robin of Spring
Schlessinger, J., & Lemmon, M. A. (2006) · Cell · doi:10.1016/j.cell.2006.09.013 · Cited by 98
Larco, J. E. D., Reynolds, R. K., Carlberg, K., Engle, C. G., & Todaro, G. J. (1980) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)85758-7 · Cited by 82
Functional implication of the interaction between EGF receptor and C-SRC
Leu, T., & Maa, M.-C. (2003) · Frontiers in bioscience · doi:10.2741/980 · Cited by 81
Karnes, W. E., Weller, S. G., Adjei, P. N., Kottke, T. J., Glenn, K. S., Gores, G. J., & Kaufmann, S. H. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70312-9 · Cited by 79
Doody, J. F., Wang, Y., Patel, S. N., Joynes, C. J., Lee, S. P., Gerlak, J., Rolser, R. L., Li, Y., Steiner, P., Bassi, R., et al. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0506 · Cited by 56
Geng, L., Tan, J., Himmelfarb, E. A., Schueneman, A. J., Niermann, K. J., Fu, A., Cuneo, K. C., Kesicki, E. A., Treiberg, J., Hayflick, J. S., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3955 · Cited by 53
Garcia, Á. T., Rosen, L. S., Cunningham, C. C., Nemunaitis, J. J., Li, C., Rulewski, N., Dovholuk, A., Savage, R. E., Chan, T.-C., Bukowksi, R., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3525 · Cited by 50
Panitumumab: In the Treatment of Metastatic Colorectal Cancer
Hoy, S. M., & Wagstaff, A. J. (2006) · Drugs · doi:10.2165/00003495-200666150-00011 · Cited by 39
Cited by
Danhier, F., Feron, O., & Préat, V. (2010) · Journal of Controlled Release · doi:10.1016/j.jconrel.2010.08.027 · Cited by 2,800
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Insight into nanoparticle cellular uptake and intracellular targeting
Yameen, B., Choi, W. I., Vilos, C., Swami, A., Shi, J., & Farokhzad, O. C. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.06.038 · Cited by 787
The pros and cons of phytoestrogens
Patisaul, H. B., & Jefferson, W. (2010) · Frontiers in Neuroendocrinology · doi:10.1016/j.yfrne.2010.03.003 · Cited by 746
Lipid-Based Drug Delivery Systems in Cancer Therapy: What Is Available and What Is Yet to Come
Yingchoncharoen, P., Kalinowski, D. S., & Richardson, D. R. (2016) · Pharmacological Reviews · doi:10.1124/pr.115.012070 · Cited by 744
Metadata
- Authors
- Lurje, G., & Lenz, H.-J.
- Venue
- Oncology
- Publisher
- S. Karger AG
- Published
- 2009
- Volume
- 77
- Issue
- 6
- Pages
- 400-410
- ISSN
- 0030-2414 (ISSN-L)
- 1423-0232
- OpenAlex
- W2009644972
- Cited by
- 442
- References
- 108
- FWCI
- 22.68
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.